Creative Biolabs provides various high-quality cationic liposome products for your research. Formulations containing different lipid compositions and cationic lipid species are listed below for the best benefit of your requirements. The default particle size of the liposome is 100nm. Fluorescent dyes, PEGylation, and particle size are also highly adjustable.
Lipid-based carriers are the most widely used non-viral vector for the delivery of nucleic acids. Cationic liposomes are particularly attractive and well developed for their high biocompatibility, ease of synthesis and modification. The positive charge of cationic liposomes is obtained from the polar headgroup of cationic lipids, which includes quaternary ammonium salts, amines (primary, secondary, and tertiary), guanidine, and heterocyclic compounds. Cationic lipids with quaternary ammonium headgroups such as 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyloxy-3-(trimethylammonium)-propane (DOTAP), and dimethyl-dioctadecyl ammonium bromide (DDAB) can bind nucleic acids tightly through charge absorption and are widely used in the formulation of cationic liposomes. Cholesterol and phosphatidylethanolamine (PE) are also common components of cationic liposomes. Cholesterol can be inserted between lipid molecules to stabilize the structure of liposomes while DOPE can change in an acidic environment to promote membrane fusion and release nucleic acids.
The cationic liposome products of Creative Biolabs are ideal carriers for the delivery of genetic materials. You can also get a customized liposome product for your research. Please feel free to contact us if you have any questions about our services and products.
Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy
Molecular Therapy-Methods & Clinical Development
Author: Liu, C., Zhang, L., et al.
The interaction between the protein corona (PC) and cationic liposomes (CLs) significantly influences the behavior and efficacy of CLs in gene delivery. The PC can obscure the surface charge and targeting ligands of CLs, leading to increased size, aggregation, and off-target effects. This phenomenon poses challenges for the use of CLs in cancer gene therapy, as it can hinder their ability to effectively target and penetrate tumor cells. Moreover, most CLs are rapidly cleared by macrophages, further limiting their therapeutic potential. However, it is noted that PEGylated CLs (PEG-CLs) can mitigate these issues to some extent by reducing protein adsorption. Understanding these interactions and challenges is crucial for developing strategies to enhance the efficacy of cationic liposomes in delivering genes for cancer treatment. This knowledge highlights the importance of carefully designing and modifying CLs to overcome the barriers presented by the protein corona and achieve optimal therapeutic outcomes.
Fig. 1 Co-administration of clodronate and doxorubicin liposomes
Online Inquiry
Cat | Product name | Lipid Composition | Fluorescent Dye | Data sheet | MSDS | Inquiry |
---|---|---|---|---|---|---|
LDLY-0123-LY170 | DOTAP:DOPE (50:50) Liposomes | DOTAP: 50M DOPE:50M |
Inquiry | |||
LDLY-0123-LY171 | DOTAP Liposomes | Inquiry | ||||
LDLY-0123-LY172 | DOTAP:Chol (50:50) Liposomes | DOTAP: 50M Chol: 50M |
Inquiry | |||
LDLY-0123-LY173 | DOTAP:Chol:DOPE (10:75:5) Liposomes | DOTAP: 10M Chol: 75M DOPE: 5M |
Inquiry | |||
LDLY-0123-LY174 | 0.5% DiI Encapsulated DOTAP Liposomes | 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) | Inquiry | |||
LDLY-0123-LY175 | 0.5% DiO Encapsulated DOTAP Liposomes | 3,3'-dilinoleyloxacarbocyanine perchlorate (DiO) | Inquiry | |||
LDLY-0123-LY176 | 0.5% NBD-DOPE Encapsulated DOTAP:Chol (50:50) Liposomes | DOTAP: 50M Chol: 50M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE) | Inquiry | ||
LDLY-0123-LY177 | 0.5% Rhod-PE Encapsulated DOTAP:Chol (50:50) Liposomes | DOTAP: 50M Chol: 50M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhod-PE) | Inquiry | ||
LDLY-0123-LY178 | 0.5% NBD-DOPE Encapsulated DOTAP:DOPE (50:50) Liposomes | DOTAP: 50M DOPE:50M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE) | Inquiry | ||
LDLY-0123-LY179 | 0.5% Rhod-PE Encapsulated DOTAP:DOPE (50:50) Liposomes | DOTAP: 50M DOPE:50M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhod-PE) | Inquiry | ||
LDLY-0123-LY180 | 0.5% NBD-DOPE Encapsulated DOTAP:Chol:DOPE (10:75:5) Liposomes | DOTAP: 10M Chol: 75M DOPE: 5M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE) | Inquiry | ||
LDLY-0123-LY181 | 0.5% Rhod-PE Encapsulated DOTAP:Chol:DOPE (10:75:5) Liposomes | DOTAP: 10M Chol: 75M DOPE: 5M |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhod-PE) | Inquiry | ||
LDLY-0123-LY182 | DDAB Liposomes | Inquiry | ||||
LDLY-0123-LY183 | DDAB:Chol (50:50) Liposomes | DDAB: 50M Chol: 50M |
Inquiry | |||
LDLY-0123-LY184 | DDAB:DOPE (50:50) Liposomes | DDAB: 50M DOPE:50M |
Inquiry |